Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
NCT06106477 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-08-13
Summary
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine therapy (AET).
Conditions
Interventions
- BEHAVIORAL
-
Intermittent Fasting
Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of: * An approximately fourteen-hour nightly fasting period that is followed by * An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM).
Sponsors & Collaborators
-
Medical College of Wisconsin
lead OTHER
Principal Investigators
-
Sailaja Kamaraju, MD · Medical College of Wisconsin
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-19
- Primary Completion
- 2026-07-15
- Completion
- 2026-07-15
Countries
- United States
Study Locations
More Related Trials
-
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
NCT06361940 ·Status: RECRUITING ·Phase: PHASE2
-
Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer
NCT02486796 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT06557057 ·Status: RECRUITING
-
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
NCT02769104 ·Status: UNKNOWN ·Phase: PHASE3
-
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
NCT00206414 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
NCT05025059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer
NCT07180914 ·Status: NOT_YET_RECRUITING
-
Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
NCT00003771 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
NCT01080170 ·Status: COMPLETED
-
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
NCT00002646 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
NCT03625635 ·Status: UNKNOWN ·Phase: NA
-
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
NCT01196936 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tamoxifen in Treating Women With Breast Cancer
NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer
NCT04142476 ·Status: TERMINATED ·Phase: NA
-
Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"
NCT05103644 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
NCT03219476 ·Status: COMPLETED ·Phase: PHASE2
-
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542 ·Status: COMPLETED ·Phase: PHASE3
-
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
NCT03953157 ·Status: COMPLETED ·Phase: NA
-
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
NCT04268134 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
NCT00916162 ·Status: COMPLETED
-
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
NCT00549822 ·Status: TERMINATED ·Phase: PHASE2
-
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
NCT00416715 ·Status: COMPLETED ·Phase: PHASE2
-
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
NCT00463489 ·Status: COMPLETED ·Phase: NA
-
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
NCT00003099 ·Status: COMPLETED ·Phase: PHASE2